International Clinical Trial: A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532304) titled 'A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)' on April 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Merck Sharp & Dohme LLC

Condition: Healthy

Intervention: Drug: Bictegravir/emtricitabine/tenofovir alafenamide Drug: Dolutegravir

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 11, 2026

Target Sample Size: 16

To know more, visit https://cli...